Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SCD | O00767 | 11/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.44 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2817668 | 1.00 | ALDH1A1 (0.49) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2817672 | 1.00 | ALDH1A1 (0.49) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19702748 | 0.92 | MAPT (0.48) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19703193 | 0.92 | MEN1 (0.48) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19703191 | 0.92 | ALDH1A1 (0.48) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19703192 | 0.92 | MEN1 (0.48) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19703016 | 0.89 | SCD (0.42) | SCDEPHX2TRPA1 | |
| SCHEMBL19703018 | 0.89 | SCD (0.42) | SCDEPHX2TRPA1 | |
| SCHEMBL11965447 | 0.88 | ALDH1A1 (0.48) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL19702645 | 0.88 | ALDH1A1 (0.49) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242286-B2 | Phenoxy-pyrrolidine derivative and its use and compositions | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2012-08-14 | — | — | US | claimed |
| EP-2173711-B1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | GRACEWAY PHARMACEUTICALS LLC (US) | 2010-11-17 | — | — | EP | claimed |
| US-20100247471-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-09-30 | — | — | US | claimed |
| EP-2173711-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | Graceway Pharmaceuticals, LLC (US) | 2010-04-14 | — | — | EP | claimed |
| WO-2009019566-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-12 | — | — | WO | claimed |
| US-20240189275-A1 | METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS WITH A SCD-1 INHIBITOR | LIPIDIO PHARMACEUTICALS, INC. (US) | 2024-06-13 | — | — | US | disclosed |
| CN-117396223-A | Methods of treating nonalcoholic steatohepatitis using SCD-1 inhibitors | 利皮迪奥制药公司 | 2024-01-12 | — | — | CN | disclosed |
| US-10973810-B2 | Methods for the treatment of neurological disorders | YUMANITY THERAPEUTICS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200306248-A1 | FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF, SAME | GDD THERAPEUTICS, LLC (US) | 2020-10-01 | — | — | US | disclosed |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2018-07-12 | — | — | US | disclosed |
| WO-2017214201-A1 | FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF, SAME | THESAN PHARMACEUTICALS, INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| US-8980936-B2 | Phenoxy-pyrrolidine derivative and its use and compositions | THESAN PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2173711-B1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | GRACEWAY PHARMACEUTICALS LLC (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-2173711-B1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | GRACEWAY PHARMACEUTICALS LLC (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20100247471-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100247471-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| US-20100247471-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-09-30 | — | — | US | disclosed |
| EP-2173711-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | Graceway Pharmaceuticals, LLC (US) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009019566-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009019566-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | PFIZER INC. (US) | 2009-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100247471-A1 | PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS | SCD, SCD5, FADS2 | ALDH1A1 1401/4885GAA 889/4885MAPT 1685/4885 |
| US-10973810-B2 | Methods for the treatment of neurological disorders | NLN, CLN6, OTC | ALDH1A1 934/4885GAA 110/4885MAPT 118/4885 |
| US-20180193325-A1 | METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | NLN, CLN6, OTC | ALDH1A1 934/4885GAA 110/4885MAPT 118/4885 |
| US-20200306248-A1 | FORMULATIONS FOR SUBSTITUTED 3-PYRROLIDINES, COMPOSITIONS CONTAINING, AND USES OF, SAME | SLC7A1, ABCG2, SLC46A1 | ALDH1A1 931/4885GAA 108/4885MAPT 2779/4885 |
| US-20240189275-A1 | METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS WITH A SCD-1 INHIBITOR | SCD, SCD5, FABP1 | ALDH1A1 381/4885GAA 593/4885MAPT 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.